sts - About 50% of patients on statins stop taking them within a year of getting a prescription
Approximately 15-20% don't take statins due to intolerance
So we are still talking millions of high risk patients who could potentially benefit from V alone. Although nothing will happen soon I could see a study using V alone in the future (especially if BP owns V). That is still a big market. As you suggest RWE data may help in this as well.